Navigation Links
Farmers can spot lame sheep, but fail to prevent footrot spread
Date:10/13/2008

Sheep farmers are highly able to spot even mildly lame sheep, but many do not take steps to prevent the spread of lameness in their flocks by catching and treating these animals. A study in the open access journal BMC Veterinary Research is the first to provide evidence for the accuracy of farmers' reporting of lameness, suggesting that farmers have one of the skills required to minimise footrot and other infectious foot conditions in their flocks.

Footrot, one of the most common causes of lameness, is infectious, caused by the bacterium Dichelobacter nodosus. Previous studies have shown that the rapid treatment of a sheep with footrot increases its rate of recovery and decreases transmission of the infection to other sheep. But are sheep farmers able to pick out sheep in the early stages of the disease?

Dr. Jasmeet Kaler and Professor Laura Green, researchers at the University of Warwick, asked more than 230 farmers and sheep specialists to watch video clips of individual sheep and then say whether they thought the sheep was lame or not. They were then asked about when they would catch the sheep for inspection and treatment, or whether they would wait until more sheep in the flock displayed a similar level of lameness.

More than 90% of the study participants correctly identified mildly lame sheep, that is, those with an uneven posture, a shorter stride in one leg or a slight nodding of the head as they moved. However, the treatment of lame sheep varied considerably between farmers. Nearly 20% said they would treat lame animals on the first day, whilst about 70% said they would do so within a week. Farmers and sheep specialists were more likely to catch and treat a sheep as the severity of its lameness increased. The majority said they would catch a single lame sheep at the point where it would not bear its weight when standing and showed discomfort when moving. However, 25 farmers said they did not catch individual sheep at a
'/>"/>

Contact: Charlotte Webber
charlotte.webber@biomedcentral.com
44-020-763-19980
BioMed Central
Source:Eurekalert

Page: 1 2

Related biology news :

1. Rising energy, food prices major threats to wetlands as farmers eye new areas for crops
2. US Patent Office rejects companys claim for bean commonly grown by Latin American farmers
3. Smithsonians National Museum of Natural History reveals ants as fungus farmers
4. What farmers think about GM crops
5. Gates funding to help poor rice farmers
6. Alliance for a Green Revolution in Africa commits 180M to revive farmers depleted soils
7. Agriculture experts meet in Beijing to examine impacts of food prices and climate change on farmers
8. Pig study sheds new light on the colonisation of Europe by early farmers
9. Statins may prevent miscarriages
10. Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
11. JDRF funded study links hygiene hypothesis to diabetes prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)PHILADELPHIA Mexican-American adolescents exposed to cigarette smoking scenes in movies are more likely to pick up the habit themselves, and this may be part of the acculturation process associated w
(Date:12/2/2009)PHILADELPHIA Assurance of a cancer-free status did not prompt people participating in a long-term computerized tomography (CT) lung-cancer screening program to pick up their cigarettes again, researc
(Date:12/2/2009)Recalls of ground beef, peanut butter, and other foods have done more than raise public awareness and concern about food safety. They also are quietly fueling a boom in the market for food testing equ
Breaking Biology News(10 mins):Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Ligon Discovery Announces Appointment of Errol B De Souza as Executive Chairman 6480 1Ligon Discovery Announces Appointment of Errol B De Souza as Executive Chairman 6480 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 1NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 3Burnout and mental distress strongly related to errors by US surgeons 61962 1Burnout and mental distress strongly related to errors by US surgeons 61962 2
...rial suggests that long-term use of candesartan, a...gnificantly reduce the symptoms of genetic heart d... effects of candesartan on left ventricular hypert... cardiomyopathy: a pilot, randomized study," appea...ar Diagnostics . , Hypertrophic cardiomyopathy, o...
...ered that grazing animals such as deer and rabbits...drupling its prevalence in some cases and encoura...ore than 20 million acres of native grasslands in ...ad been predicted by other theories, which had sug... contain or reduce disease. They point once again ...
... emerging field of nutrigenomics, which aims to i...y,s response to diet and studies how the bioactive...xplored in a series of provocative, interdisciplin...ial Issue (Volume 12, number 4) of OMICS: A Journ...l published by Mary Ann Liebert, Inc. ( www.lieber...
Other Biology News:Grazing animals help spread plant disease 2Nutrigenomics -- developing personalized diets for disease prevention 2
(Date:12/6/2009)...DGEFIELD, Conn., Dec. 6 Boehringer...ER(TM) study investigating dabigatran etexilate (1...compared to dose-adjusted warfarin in patients wit...at the 51st American Society of Hematology Annual ... New England Journal of Medicine .(1) ,, Dabi...
(Date:12/4/2009)Researchers from the National Institute of Standards and Technology (NIST) and the Naval Research Laboratory have developed a new way to introduce magnetic impurities in a semiconductor crystal by pro
(Date:12/4/2009)CORALVILLE, Iowa, Dec. 4 Vivakor, Inc. (OTC Bulletin Board: VIVK) today confirmed that its shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmer
(Date:12/4/2009)Alberta Centre for Advanced Micro Nano Technology Products (ACAMP) hosts, health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ACAMP hosted a health & medical seminar, explaini
Breaking Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6NIST researchers put a new spin on atomic musical chairs 2Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3Alberta companies delivering new products to the health & medical marketplace 2
..., March 12 Micromet, Inc. (Nasdaq: MITI ), a bi...ary antibodies for the treatment of cancer, inflam...at it is regaining from its partner MedImmune the ...antibody candidate, blinatumomab, also known as MT...linical trial with blinatumomab for the treatment ...
... 12 Albert Liou, Corporate Vice President and Gen...national Corporation (Nasdaq: PRXL ), a leading ...resent "The True Value of Incorporating Asia into ...Medical Asia 2009 conference, to be held March 16 ...onvention & Exhibition Centre in Singapore. Mr...
...nds to acquire all outstanding shares of Genentech...nd early development to operate as an independent ...rters of combined U.S. commercial operations; Gene...novation will be enhanced through a diversity of r..., partnerships and other key assets , , -- Transa...
Other Biology Technology:Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 2PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 3PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 4Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 2Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 3Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 4Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 5Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 6Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 7
LEVAMISOLE SOLUTION from Invitrogen
Rabbit Anti-Human UCP2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Catch and Release® v2.0
Reversible Immunoprecipitation System from Upstate
DTNB from Cayman Chemical
Biology Products: